Plain-English translation of NCT06048094 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a special type of imaging scan called 18F-Fluciclovine PET can help doctors see how well radiation therapy is working to treat cancer that has spread to the brain. You would receive two of these imaging scans — one before your radiation treatment and one eight weeks after — to help doctors understand if the treatment is helping you.
Currently, doctors don't have a good way to quickly tell if radiation therapy for brain tumors is working. This study is trying to see if this new imaging scan can give doctors better information sooner, so they can adjust your treatment plan if needed.
You likely qualify if…
You likely don't qualify if…
You would have two imaging scans as part of this study. First, you'll have one scan at the time your radiation treatment is being planned. Then, you'll receive your radiation therapy as normal (this is standard care, not experimental). About eight weeks later, you'll return for a second imaging scan to see how your tumors have responded to the treatment. The whole study takes about two months.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Baptist Health South Florida
Collaborators
Blue Earth Diagnostics
Enrollment target
~46 participants
Started
April 2024
Primary completion
June 2032
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rupesh Kotecha, M.D.
Miami Cancer Institute at Baptist Health, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.